229 results on '"Guo, Yongli"'
Search Results
2. Enhancing logistics performance measurement: an effectiveness-based hierarchical data envelopment analysis approach
3. Temporal dynamics of water level and water sources analyses of karst tidal springs in Guilin, China
4. LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma
5. Crop Yield Estimation Considering Plant Characteristics and Combining Photosynthetic Area Index
6. Hypoglycemic activities of flowers of Xanthoceras sorbifolia and identification of anti-oxidant components by off-line UPLC-QTOF-MS/MS-free radical scavenging detection
7. Hydrogeological functioning of a karst underground river basin in southwest China
8. Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
9. Translational practice of fluorescence in situ hybridisation to identify neuroblastic tumours with TERT rearrangements
10. Influence of Anthropogenic Sulfuric Acid on Different Lithological Carbonate Weathering and the Related Carbon Sink Budget: Examples from Southwest China
11. Hyaluronic acid-modified and verteporfin-loaded polylactic acid nanogels promote scarless wound healing by accelerating wound re-epithelialization and controlling scar formation
12. BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma
13. Epidemiological characteristics of paediatric burn patients in China from 2016 to 2019: a retrospective study
14. Biological Activity of Optimized Codon Bovine Type III Interferon Expressed in Pichia pastoris
15. TAF1D promotes proliferation by transcriptionally activating G2 /M phase‐related genes inMYCN‐amplified neuroblastoma
16. Biological Activity of Optimized Codon Bovine Type III Interferon Expressed in Pichia Pastoris
17. Data from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
18. Supplementary Figure 1 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
19. Supplementary Figure 5 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
20. Supplementary Figure 1 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
21. Supplementary Figure 2 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
22. Supplementary Figure 1 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
23. Data from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
24. Supplementary Figure 4 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
25. Supplementary Figure Legend from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
26. Data from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
27. Supplementary Figure 5 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
28. Supplementary Figure 6 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
29. Supplementary Figure 7 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
30. Supplementary Figure Legend from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
31. Supplementary Figure 7 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
32. Supplementary Figure 1 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
33. Supplementary Figure 3 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
34. Supplementary Figure 4 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
35. Supplementary Figure Legend from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
36. Supplementary Figure 3 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
37. Supplementary Figure 2 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
38. Supplementary Figure 3 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
39. Supplementary Figure 6 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
40. Supplementary Figure 2 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
41. Supplementary Figure Legend from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
42. Supplementary Figure 3 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
43. Supplementary Figure 2 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
44. Supplementary Tables S1-S5 from Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
45. Supplementary Fig. S1 from UBE1L causes lung cancer growth suppression by targeting cyclin D1
46. Supplementary Fig. S1 from UBE1L causes lung cancer growth suppression by targeting cyclin D1
47. Supplementary Tables S1-S5 from Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
48. Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
49. Supplementary Figure 1 from Blockade of the Ubiquitin Protease UBP43 Destabilizes Transcription Factor PML/RARα and Inhibits the Growth of Acute Promyelocytic Leukemia
50. Supplementary Figure 1 from Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.